Fig. 2.

Co-inhibition of BCL-2 and MCL-1 using BCL-2 selective inhibitors ABT-199 and S63845. Cervical cancer cell lines (a) HeLa; (b) C33A; (c) SiHa and (d) CaSki cells were treated with increasing concentrations of ABT-199 (0–32 μM) in the presence and absence of S63845. Points represent mean ± SEM of four experiments.